{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:16:59Z","timestamp":1790813819153,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004776","name":"Faculty of Medicine, Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1053\/j.ajkd.2019.05.011","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T08:07:24Z","timestamp":1563523644000},"page":"601-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial"],"prefix":"10.1053","volume":"74","author":[{"given":"Thidarat","family":"Kitrungphaiboon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongpratch","family":"Puapatanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyatida","family":"Chuengsaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krittaya","family":"Tiskajornsiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guttiga","family":"Halue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monchai","family":"Siribamrungwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saraporn","family":"Matayart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamonrat","family":"Chongthanakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ussanee","family":"Poonvivatchaikarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchana","family":"Boonyakrai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanida","family":"Somboonsilp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pisut","family":"Katavetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kearkiat","family":"Praditpornsilpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Eiam-Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talerngsak","family":"Kanjanabuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2019.05.011_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1476-0711-5-6","article-title":"Treatment and outcome of CPD-associated peritonitis","volume":"5","author":"Troidle","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"8","key":"10.1053\/j.ajkd.2019.05.011_bib2","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2011121135","article-title":"Recent peritonitis associates with mortality among patients treated with peritoneal dialysis","volume":"23","author":"Boudville","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2019.05.011_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3747\/pdi.2010.00049","article-title":"Peritoneal dialysis-related infections recommendations: 2010 update","volume":"30","author":"Li","year":"2010","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.ajkd.2019.05.011_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3747\/pdi.2016.00078","article-title":"ISPD peritonitis recommendations: 2016 update on prevention and treatment","volume":"36","author":"Li","year":"2016","journal-title":"Perit Dial Int"},{"issue":"5","key":"10.1053\/j.ajkd.2019.05.011_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/089686080402400508","article-title":"Cefazolin plus ceftazidime versus imipenem\/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial","volume":"24","author":"Leung","year":"2004","journal-title":"Perit Dial Int"},{"issue":"5","key":"10.1053\/j.ajkd.2019.05.011_bib6","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/j.1523-1755.2005.00700.x","article-title":"Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function","volume":"68","author":"Lui","year":"2005","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2019.05.011_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/089686080002000212","article-title":"Use of intraperitoneal cefepime as monotherapy in treatment of CAPD peritonitis","volume":"20","author":"Li","year":"2000","journal-title":"Perit Dial Int"},{"issue":"1","key":"10.1053\/j.ajkd.2019.05.011_bib8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/ajkd.2001.25205","article-title":"Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis","volume":"38","author":"Wong","year":"2001","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2019.05.011_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003495-199447030-00007","article-title":"Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use","volume":"47","author":"Barradell","year":"1994","journal-title":"Drugs"},{"issue":"4","key":"10.1053\/j.ajkd.2019.05.011_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jac\/17.4.441","article-title":"The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin","volume":"17","author":"Neu","year":"1986","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"10","key":"10.1053\/j.ajkd.2019.05.011_bib11","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","article-title":"Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement","volume":"295","author":"Piaggio","year":"2006","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2019.05.011_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/1471-2334-14-445","article-title":"Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: a proportional meta-analysis","volume":"14","author":"Barretti","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.ajkd.2019.05.011_bib13","series-title":"Sample Size Calculations in Clinical Research","author":"Chow","year":"2007"},{"issue":"2","key":"10.1053\/j.ajkd.2019.05.011_bib14","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1053\/j.ajkd.2014.02.025","article-title":"Peritoneal dialysis-related peritonitis: towards\u00a0improving evidence, practices, and outcomes","volume":"64","author":"Cho","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2019.05.011_bib15","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1093\/jac\/dkr024","article-title":"Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study","volume":"66","author":"Song","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1053\/j.ajkd.2019.05.011_bib16","first-page":"218","article-title":"Cefazolin and netilmycin versus vancomycin and ceftazidime in the treatment of CAPD peritonitis","volume":"13","author":"Gucek","year":"1997","journal-title":"Adv Perit Dial"},{"issue":"1","key":"10.1053\/j.ajkd.2019.05.011_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/089686089701700119","article-title":"Intraperitoneal once-daily dose of cefazolin and gentamicin for treating CAPD peritonitis","volume":"17","author":"Lai","year":"1997","journal-title":"Perit Dial Int"},{"issue":"7","key":"10.1053\/j.ajkd.2019.05.011_bib18","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1128\/AAC.36.7.1387","article-title":"Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis","volume":"36","author":"Barbhaiya","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1053\/j.ajkd.2019.05.011_bib19","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1345\/aph.18336","article-title":"Stability of cefepime in peritoneal dialysis solution","volume":"33","author":"Williamson","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1053\/j.ajkd.2019.05.011_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/089686080902900101","article-title":"Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use","volume":"29","author":"de Vin","year":"2009","journal-title":"Perit Dial Int"},{"key":"10.1053\/j.ajkd.2019.05.011_bib21","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/sj.ki.5001916","article-title":"Microbiology and outcomes of peritonitis in North America","volume":"103","author":"Mujais","year":"2006","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"10.1053\/j.ajkd.2019.05.011_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1469-0691.2005.01222.x","article-title":"Change in bacterial aetiology of peritoneal dialysis-related peritonitis over 10 years: experience from a centre in South-East Asia","volume":"11","author":"Szeto","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 4","key":"10.1053\/j.ajkd.2019.05.011_bib23","first-page":"S7","article-title":"The incidence of peritoneal dialysis-related infection in Thailand: a nationwide survey","volume":"94","author":"Kanjanabuch","year":"2011","journal-title":"J\u00a0Med Assoc Thai"},{"issue":"1","key":"10.1053\/j.ajkd.2019.05.011_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/039139880803100107","article-title":"Peritoneal dialysis-related peritonitis in southern Thailand","volume":"31","author":"Nakwan","year":"2008","journal-title":"Int J Artif Organs"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2019.05.011_bib25","first-page":"S138","article-title":"Risk factors of first peritonitis episode in Thai CAPD patients","volume":"89","author":"Sirivongs","year":"2006","journal-title":"J\u00a0Med Assoc Thai"},{"issue":"3","key":"10.1053\/j.ajkd.2019.05.011_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1592\/phco.23.3.369.32100","article-title":"Retrospective review of neurotoxicity induced by cefepime and ceftazidime","volume":"23","author":"Chow","year":"2003","journal-title":"Pharmacotherapy"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619307966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638619307966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:20:56Z","timestamp":1759461656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638619307966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0272638619307966"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.05.011","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}